Similarity Score |
Similarity Level |
Drug ID |
Developmental Stage |
1.0 |
High Similarity |
NPD338 |
Approved |
0.9929 |
High Similarity |
NPD339 |
Approved |
0.9857 |
High Similarity |
NPD283 |
Approved |
0.9718 |
High Similarity |
NPD242 |
Approved |
0.9583 |
High Similarity |
NPD169 |
Phase 2 |
0.9429 |
High Similarity |
NPD249 |
Approved |
0.9429 |
High Similarity |
NPD250 |
Approved |
0.9296 |
High Similarity |
NPD195 |
Approved |
0.9296 |
High Similarity |
NPD186 |
Discovery |
0.9014 |
High Similarity |
NPD185 |
Approved |
0.8954 |
High Similarity |
NPD247 |
Clinical (unspecified phase) |
0.8919 |
High Similarity |
NPD1750 |
Clinical (unspecified phase) |
0.8919 |
High Similarity |
NPD3107 |
Discontinued |
0.8919 |
High Similarity |
NPD1369 |
Phase 2 |
0.8917 |
High Similarity |
NPD4171 |
Clinical (unspecified phase) |
0.8889 |
High Similarity |
NPD166 |
Approved |
0.8873 |
High Similarity |
NPD193 |
Suspended |
0.8861 |
High Similarity |
NPD1412 |
Clinical (unspecified phase) |
0.8831 |
High Similarity |
NPD7988 |
Suspended |
0.875 |
High Similarity |
NPD4716 |
Approved |
0.8742 |
High Similarity |
NPD2624 |
Phase 2 |
0.8742 |
High Similarity |
NPD1732 |
Phase 3 |
0.8742 |
High Similarity |
NPD2646 |
Discontinued |
0.8696 |
High Similarity |
NPD4744 |
Clinical (unspecified phase) |
0.8636 |
High Similarity |
NPD3083 |
Approved |
0.8523 |
High Similarity |
NPD548 |
Clinical (unspecified phase) |
0.8497 |
Intermediate Similarity |
NPD217 |
Approved |
0.8497 |
Intermediate Similarity |
NPD219 |
Phase 3 |
0.8497 |
Intermediate Similarity |
NPD218 |
Approved |
0.8497 |
Intermediate Similarity |
NPD216 |
Approved |
0.8497 |
Intermediate Similarity |
NPD220 |
Clinical (unspecified phase) |
0.8485 |
Intermediate Similarity |
NPD6417 |
Clinical (unspecified phase) |
0.8383 |
Intermediate Similarity |
NPD2632 |
Approved |
0.8383 |
Intermediate Similarity |
NPD2630 |
Approved |
0.8383 |
Intermediate Similarity |
NPD2631 |
Clinical (unspecified phase) |
0.8302 |
Intermediate Similarity |
NPD2647 |
Phase 3 |
0.8301 |
Intermediate Similarity |
NPD214 |
Approved |
0.8301 |
Intermediate Similarity |
NPD213 |
Clinical (unspecified phase) |
0.8112 |
Intermediate Similarity |
NPD248 |
Discontinued |
0.8049 |
Intermediate Similarity |
NPD5666 |
Phase 2 |
0.8042 |
Intermediate Similarity |
NPD9633 |
Phase 3 |
0.8025 |
Intermediate Similarity |
NPD546 |
Clinical (unspecified phase) |
0.8013 |
Intermediate Similarity |
NPD7158 |
Phase 1 |
0.7986 |
Intermediate Similarity |
NPD9632 |
Phase 3 |
0.7958 |
Intermediate Similarity |
NPD9408 |
Phase 3 |
0.7901 |
Intermediate Similarity |
NPD1776 |
Approved |
0.7901 |
Intermediate Similarity |
NPD1777 |
Approved |
0.7871 |
Intermediate Similarity |
NPD3085 |
Phase 1 |
0.7862 |
Intermediate Similarity |
NPD4074 |
Clinical (unspecified phase) |
0.7847 |
Intermediate Similarity |
NPD870 |
Clinical (unspecified phase) |
0.7838 |
Intermediate Similarity |
NPD252 |
Clinical (unspecified phase) |
0.7821 |
Intermediate Similarity |
NPD3086 |
Phase 3 |
0.7719 |
Intermediate Similarity |
NPD1692 |
Approved |
0.7654 |
Intermediate Similarity |
NPD516 |
Clinical (unspecified phase) |
0.7632 |
Intermediate Similarity |
NPD3695 |
Approved |
0.7632 |
Intermediate Similarity |
NPD3696 |
Approved |
0.7632 |
Intermediate Similarity |
NPD549 |
Approved |
0.763 |
Intermediate Similarity |
NPD5682 |
Phase 3 |
0.763 |
Intermediate Similarity |
NPD5683 |
Clinical (unspecified phase) |
0.763 |
Intermediate Similarity |
NPD5684 |
Clinical (unspecified phase) |
0.76 |
Intermediate Similarity |
NPD4054 |
Clinical (unspecified phase) |
0.7533 |
Intermediate Similarity |
NPD194 |
Clinical (unspecified phase) |
0.7438 |
Intermediate Similarity |
NPD536 |
Clinical (unspecified phase) |
0.7308 |
Intermediate Similarity |
NPD582 |
Approved |
0.7261 |
Intermediate Similarity |
NPD4240 |
Approved |
0.7215 |
Intermediate Similarity |
NPD171 |
Discontinued |
0.7205 |
Intermediate Similarity |
NPD3708 |
Phase 2 |
0.7191 |
Intermediate Similarity |
NPD7138 |
Phase 2 |
0.716 |
Intermediate Similarity |
NPD353 |
Discontinued |
0.7135 |
Intermediate Similarity |
NPD1063 |
Phase 2 |
0.7012 |
Intermediate Similarity |
NPD231 |
Clinical (unspecified phase) |
0.6984 |
Remote Similarity |
NPD2965 |
Clinical (unspecified phase) |
0.6947 |
Remote Similarity |
NPD2876 |
Phase 3 |
0.6947 |
Remote Similarity |
NPD2877 |
Clinical (unspecified phase) |
0.6939 |
Remote Similarity |
NPD5080 |
Phase 2 |
0.6909 |
Remote Similarity |
NPD9605 |
Phase 3 |
0.6888 |
Remote Similarity |
NPD5079 |
Phase 2 |
0.6875 |
Remote Similarity |
NPD2824 |
Phase 2 |
0.6871 |
Remote Similarity |
NPD9606 |
Approved |
0.6824 |
Remote Similarity |
NPD9607 |
Approved |
0.6798 |
Remote Similarity |
NPD1046 |
Clinical (unspecified phase) |
0.6763 |
Remote Similarity |
NPD6840 |
Approved |
0.6735 |
Remote Similarity |
NPD2903 |
Clinical (unspecified phase) |
0.6735 |
Remote Similarity |
NPD2902 |
Phase 2 |
0.6688 |
Remote Similarity |
NPD209 |
Clinical (unspecified phase) |
0.6667 |
Remote Similarity |
NPD9409 |
Discontinued |
0.6633 |
Remote Similarity |
NPD4495 |
Phase 1 |
0.6624 |
Remote Similarity |
NPD545 |
Clinical (unspecified phase) |
0.6554 |
Remote Similarity |
NPD9374 |
Approved |
0.6552 |
Remote Similarity |
NPD527 |
Clinical (unspecified phase) |
0.6545 |
Remote Similarity |
NPD1730 |
Discontinued |
0.6531 |
Remote Similarity |
NPD9373 |
Approved |
0.6519 |
Remote Similarity |
NPD547 |
Clinical (unspecified phase) |
0.6494 |
Remote Similarity |
NPD9084 |
Phase 2 |
0.649 |
Remote Similarity |
NPD307 |
Approved |
0.6456 |
Remote Similarity |
NPD282 |
Approved |
0.6438 |
Remote Similarity |
NPD1119 |
Phase 2 |
0.6369 |
Remote Similarity |
NPD775 |
Approved |
0.633 |
Remote Similarity |
NPD2152 |
Clinical (unspecified phase) |
0.6303 |
Remote Similarity |
NPD1431 |
Approved |
0.6303 |
Remote Similarity |
NPD2253 |
Discontinued |
0.6303 |
Remote Similarity |
NPD1430 |
Approved |
0.6289 |
Remote Similarity |
NPD8829 |
Clinical (unspecified phase) |
0.6273 |
Remote Similarity |
NPD1058 |
Discontinued |
0.6273 |
Remote Similarity |
NPD9083 |
Clinical (unspecified phase) |
0.6243 |
Remote Similarity |
NPD207 |
Discontinued |
0.6225 |
Remote Similarity |
NPD9584 |
Phase 2 |
0.6224 |
Remote Similarity |
NPD4459 |
Clinical (unspecified phase) |
0.6224 |
Remote Similarity |
NPD4458 |
Phase 2 |
0.6213 |
Remote Similarity |
NPD7531 |
Clinical (unspecified phase) |
0.6164 |
Remote Similarity |
NPD1127 |
Approved |
0.6164 |
Remote Similarity |
NPD8836 |
Approved |
0.6164 |
Remote Similarity |
NPD1128 |
Approved |
0.6139 |
Remote Similarity |
NPD281 |
Approved |
0.6121 |
Remote Similarity |
NPD799 |
Phase 1 |
0.6121 |
Remote Similarity |
NPD1808 |
Phase 1 |
0.6077 |
Remote Similarity |
NPD6381 |
Phase 2 |
0.6061 |
Remote Similarity |
NPD6112 |
Approved |
0.6048 |
Remote Similarity |
NPD1118 |
Discontinued |
0.604 |
Remote Similarity |
NPD9417 |
Phase 3 |
0.604 |
Remote Similarity |
NPD9416 |
Phase 3 |
0.6026 |
Remote Similarity |
NPD9375 |
Discontinued |
0.6013 |
Remote Similarity |
NPD798 |
Discontinued |
0.6 |
Remote Similarity |
NPD1120 |
Approved |
0.6 |
Remote Similarity |
NPD1121 |
Approved |
0.6 |
Remote Similarity |
NPD535 |
Approved |
0.5956 |
Remote Similarity |
NPD9582 |
Phase 3 |
0.595 |
Remote Similarity |
NPD5486 |
Discontinued |
0.5946 |
Remote Similarity |
NPD9626 |
Clinical (unspecified phase) |
0.5944 |
Remote Similarity |
NPD2593 |
Clinical (unspecified phase) |
0.5939 |
Remote Similarity |
NPD9484 |
Clinical (unspecified phase) |
0.592 |
Remote Similarity |
NPD4713 |
Clinical (unspecified phase) |
0.592 |
Remote Similarity |
NPD34 |
Approved |
0.592 |
Remote Similarity |
NPD4714 |
Approved |
0.592 |
Remote Similarity |
NPD4715 |
Clinical (unspecified phase) |
0.5917 |
Remote Similarity |
NPD7502 |
Clinical (unspecified phase) |
0.5901 |
Remote Similarity |
NPD515 |
Phase 1 |
0.5882 |
Remote Similarity |
NPD1117 |
Clinical (unspecified phase) |
0.5867 |
Remote Similarity |
NPD8250 |
Phase 2 |
0.5867 |
Remote Similarity |
NPD1816 |
Clinical (unspecified phase) |
0.5862 |
Remote Similarity |
NPD5458 |
Discontinued |
0.5859 |
Remote Similarity |
NPD691 |
Discontinued |
0.5849 |
Remote Similarity |
NPD8830 |
Phase 3 |
0.5833 |
Remote Similarity |
NPD2450 |
Phase 2 |
0.5833 |
Remote Similarity |
NPD2451 |
Phase 2 |
0.5833 |
Remote Similarity |
NPD2452 |
Phase 2 |
0.5833 |
Remote Similarity |
NPD2453 |
Phase 2 |
0.5822 |
Remote Similarity |
NPD6036 |
Suspended |
0.5806 |
Remote Similarity |
NPD9406 |
Approved |
0.5795 |
Remote Similarity |
NPD7842 |
Phase 2 |
0.5776 |
Remote Similarity |
NPD78 |
Approved |
0.5776 |
Remote Similarity |
NPD9544 |
Approved |
0.5756 |
Remote Similarity |
NPD796 |
Phase 2 |
0.5732 |
Remote Similarity |
NPD8831 |
Approved |
0.5732 |
Remote Similarity |
NPD8833 |
Approved |
0.5705 |
Remote Similarity |
NPD757 |
Phase 3 |
0.5696 |
Remote Similarity |
NPD9360 |
Approved |
0.5683 |
Remote Similarity |
NPD5768 |
Phase 2 |
0.5682 |
Remote Similarity |
NPD5627 |
Approved |
0.5681 |
Remote Similarity |
NPD537 |
Phase 2 |
0.5681 |
Remote Similarity |
NPD534 |
Phase 2 |
0.5644 |
Remote Similarity |
NPD5665 |
Clinical (unspecified phase) |
0.5633 |
Remote Similarity |
NPD6351 |
Discovery |
0.5633 |
Remote Similarity |
NPD1368 |
Approved |
0.5625 |
Remote Similarity |
NPD3849 |
Clinical (unspecified phase) |
0.561 |
Remote Similarity |
NPD1775 |
Approved |
0.561 |
Remote Similarity |
NPD1085 |
Approved |
0.5607
|
Remote Similarity |
NPD4555 |
Clinical (unspecified phase) |